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Pathway-specific inhibition 
of primaquine metabolism by chloroquine/
quinine
Pius S. Fasinu1* , Babu L. Tekwani1,2, Bharathi Avula1, Narayan D. Chaurasiya1, N. P. Dhammika Nanayakkara1, 
Yan‑Hong Wang1, Ikhlas A. Khan1,2 and Larry A. Walker1,2
Abstract 
Background: There has been some evidence to suggest that the addition of chloroquine (CQ) or quinine (QN) to 
8‑aminoquinoline (8‑AQ) treatment regimens may increase the therapeutic efficacy of the 8‑AQ and simultaneously 
mitigate against its haemolytic toxicity. However, both CQ and QN are considered effective, although perhaps moder‑
ate inhibitors of CYP2D6, an enzyme now regarded as necessary for primaquine (PQ) pharmacologic activity. An 
understanding of the influence of CQ and QN on the metabolism of PQ may shed light on the potential mechanisms 
of the beneficial interaction.
Methods: Differential metabolism of PQ enantiomers by recombinant human CYP2D6, monoamine oxidase A 
(MAO), and cryopreserved human hepatocytes in the presence/absence of CQ and QN.
Results: Both CQ and QN significantly inhibited the activity of CYP2D6. PQ depletion by MAO and human hepato‑
cytes was not affected significantly by the presence of CQ and QN. CYP2D6‑mediated hydroxylation was largely 
suppressed by both CQ and QN. The formation of the primary deaminated metabolites, including carboxyprimaquine 
(CPQ) and cyclized side chain derivative from the aldehyde (m/z 241), was not sensitive to the presence of CQ and QN. 
However, the appearance of the glucuronides of CPQ and PQ alcohol were significantly suppressed. CQ and QN also 
inhibited the appearance of the m/z 257 metabolite with a similar pattern, suggesting that it may be derived from 
the CPQ conjugate. The apparent quinone‑imine of CPQ (m/z 289) was only partially suppressed by both QN and CQ, 
but with a differential pattern of inhibition for the two drugs. The m/z 274 (quinone‑imine of a ring‑hydroxylated PQ 
metabolite) and m/z 422 (an apparent glucose conjugate of PQ) metabolites in hepatocytes were strongly suppressed 
by both QN and CQ, perhaps a reflection of the 2D6 inhibition by these drugs. The formation of the carbamoyl glucu‑
ronide of PQ (m/z 480) was not affected by CQ/QN.
Conclusion: The metabolite‑specific interactions in the current studies seem at variance with earlier reports of the 
dependence of PQ on CYP2D6 metabolism, and enhanced PQ anti‑malarial activity/reduced toxicity in the presence 
of CQ/QN. These results suggest a complex picture in which CQ/QN may shift metabolite pathway balances towards 
a profile that retains efficacy, while reducing the formation or availability of toxic metabolites to erythrocytes. Alter‑
natively, these drugs may alter transport or distribution of PQ metabolites in a fashion that reduces toxicity while 
maintaining efficacy against the parasite.
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Background
There has been an intense renewal of interest in pri-
maquine (PQ) after over 60  years since its introduction 
into clinical medicine [1, 2]. This is understandably so 
because, despite spirited research efforts, no suitable 
alternative has yet been approved to rival the unique 
therapeutic profile of PQ. As the prototype 8-aminoqui-
noline (8-AQ), PQ is the only licensed drug capable of 
treating the relapsing liver stages (hypnozoites) of Plas-
modium vivax [3]. It is gametocytocidal against Plasmo-
dium falciparum and capable of blocking transmission. 
Additionally, PQ has been used as a prophylactic option 
against all forms of malaria [4]. It has found use in the 
treatment of artemisinin-resistant P. falciparum strains 
[5]. The major limitation in the clinical utility of PQ is its 
haemolytic toxicity in individuals with genetic deficiency 
in glucose-6-phosphate dehydrogenase (G6PD). Both 
the therapeutic and haemotoxic effects of PQ have been 
strongly linked to its metabolite(s) [6–8]. While a num-
ber of human metabolites of PQ have been described [9], 
the identity of the specific PQ metabolites responsible for 
efficacy and toxicity are not well understood [10].
Interactions between various anti-malarial drugs have 
been reported to improve efficacy and mitigate toxicity 
of PQ. In particular, there have been a number of clinical 
evidences presented over the years showing that quinine 
(QN) and chloroquine (CQ) can favourably affect the 
efficacy of 8-AQs; further, there are intriguing sugges-
tions that the haemolytic toxicity of the 8-AQ class can 
be reduced. For instance, the addition of CQ increased 
the effectiveness of PQ and pamaquine while reducing 
the associated toxicity in Korean patients [11]. In a study 
to assess the toxicity of pentaquine, using doses two- to 
three-fold higher than therapeutic doses, ten patients 
were experimentally infected with malaria. Each patient 
received 120  mg pentaquine with or without QN [12]. 
Five subjects receiving pentaquine only experienced 
marked drops in haemoglobin (average 2.6 g/dl), but the 
five concomitantly receiving QN showed no change in 
haemoglobin. Moreover, no patient in the pentaquine/
QN group had a relapse in 12 months compared to two 
in the pentaquine-only group, who had relapses in 12 
and 26 days, respectively. Associated side effects of syn-
cope and postural hypotension were not reported in the 
pentaquine/QN group compared to pentaquine-only 
group [12]. Thus, this study not only demonstrated the 
attenuation of the toxic effects of pentaquine by QN, it 
showed that QN improved the therapeutic efficacy of 
pentaquine. A similar observation, including an increase 
in plasma pentaquine concentration in the presence of 
QN, was reported by Alving and co-workers [13]. Being 
an 8-AQ like PQ, whose mechanism of toxicity might be 
similar, this observation suggests similar beneficial drug 
interactions with PQ. Since the pharmacological activ-
ity of the 8-AQs are dependent on their metabolites, 
the knowledge of the roles of each metabolites may be 
deductible from observed pharmacodynamic changes 
due to inhibition or facilitation of the formation of 
known metabolites by other agents.
The potential mechanisms underlying these interac-
tions are unknown at present, but could be presump-
tively metabolism-linked. Until recently, the focus on 
PQ metabolites in clinical studies has been towards car-
boxy-primaquine (CPQ), which has been reported to be 
the major circulating metabolite [14]. In one study con-
ducted to investigate interactions among anti-malarial 
drugs, QN caused a decrease in the area under the curve 
(AUC0–24h) of CPQ by about 50  % [15]. More recently, 
Pukrittayakamee et  al. [16] conducted an open-label, 
cross-over, pharmacokinetic interaction study in 16 
health human subjects. Volunteers received single doses 
of 30  mg PQ, 600  mg CQ, or the combination thereof. 
In contrast to the QN results, CQ caused a significant 
increase in the plasma levels of both PQ and its major 
metabolite, CPQ. Thus, these two drugs, while sharing a 
beneficial effect on PQ efficacy and toxicity, apparently 
do so by affecting mechanisms other than the monoam-
ine oxidase-mediated metabolism of PQ to CPQ. Other 
pathways of PQ metabolism, now known to be promi-
nent in human liver—but so far difficult to pinpoint their 
ultimate disposition—have not been explored from the 
perspective of CQ and QN effects.
More recent studies with PQ have developed compel-
ling evidence that the metabolism to its active metabo-
lites is dependent on the activity of cytochrome P450 2D6 
(CYP2D6) [7, 17]. This evidence is based on the failure of 
PQ therapy in CYP2D6-null metabolizers and the abla-
tion of the anti-malarial effect of PQ in CYP2D knockout 
mice. Thus, it would naturally be expected that inhibi-
tion of CYP2D6 would impair the efficacy of PQ. How-
ever, both QN and CQ have been shown to be moderate 
inhibitors of CYP2D6 with significant effects at clinically 
used doses [18, 19]. It is puzzling then, that they do not 
effectively antagonize the anti-malarial effects of PQ, and 
rather are potentiators. This suggests that either the puta-
tive dependence of PQ efficacy on CYP2D6 is incorrect, 
or that CQ and QN may be acting by other mechanisms.
Recent studies of PQ metabolism have revealed inter-
esting new information about the metabolic pathways, 
suggesting that in humans the two enantiomers of PQ 
(which is used as a racemic mixture) are differentially 
metabolized to CPQ [20]. While the R(–) form of PQ is 
readily converted to CPQ, the S(+) form is much less so, 
and in fact >95 % of the CPQ circulating is attributable to 
R(–) PQ. This raises the question as to the primary meta-
bolic route for the S(+) form. Furthermore, other studies 
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revealed several other major metabolites of PQ generated 
in human hepatocytes [21] and some of these are formed 
predominantly or exclusively from one enantiomer of PQ 
[9, 21].
Therefore, the objective of the current study was to 
investigate the effects of CQ and QN on the clearance 
and metabolism profiles of PQ and its individual enan-
tiomers by human CYP2D6, monoamine oxidase (MAO) 
and primary human hepatocytes.
Methods
Substrates, chemicals and co‑factors
Racemic, (S)-(+)- and (R)-(−)- enantiomers of 13C(6)-
labelled PQ (MW 259.1317  g/mol); PQ alcohol, 2-, 3-, 
and 4-hydroxyprimaquine and CPQ were synthesized as 
previously reported [9, 22–24]. The identity of the com-
pounds synthesized was confirmed by spectral infra-red 
(IR), nuclear magnetic resonance (NMR), high-resolution 
mass spectrometry and physical data in comparison with 
published values.
Co-factors for enzyme activity, including glucose-
6-phosphate and its dehydrogenase, reduced nicotina-
mide adenine dinucleotide phosphate and magnesium 
chloride were purchased from Sigma-Aldrich (St Louis, 
MO, USA). Analytical grade solvents, including acetoni-
trile and methanol were purchased from Fisher Scientific 
(Fair Lawn, NJ, USA). Milli-Q system (Millipore, Bed-
ford, MA, USA) was used to purify water for analytical 
utility.
Metabolic assay systems
Recombinant cytochrome-P450 supersomes containing 
CYP2D6 (1  nmol CYP/mL), and recombinant mono-
amine oxidase-A (MAO) were purchased from BD Bio-
sciences (Billerica, MA, USA) and stored at −80 °C until 
used. Cryopreserved, metabolism-qualified hepatocytes 
(mixed-gender pooled) were obtained from Corning Life 
Sciences (Woburn, MA, USA) and stored in liquid nitro-
gen tank until use. Just before use, the metabolic systems 
were thawed according to supplier instructions. Typically, 
the vials containing the cryopreserved metabolic systems 
were dipped (without submerging) into water bath set at 
37 °C for not more than 2 min in order to defrost the con-
tents. The vials are then wiped with 70 % alcohol before 
the contents are poured into the recovery medium or 
incubation buffers.
Incubations with CYP2D6 and monoamine oxidase
Typical assay with rCYP2D6 and MAO involved the 
dilution of the thawed enzymes with 0.1  mM phos-
phate buffered saline (pH 7.4), aliquot dispensing in 
clear 96-well plates, and the subsequent addition of 
the substrate (PQ) and the co-factor solution to initiate 
metabolic reactions. The final concentrations of addi-
tives in the incubation mixture of 500  µL are as fol-
lows: 20  µM PQ, 0.5  mg/mL of enzyme (CYP2D6 or 
MAO-A), 1.0  unit/ml of G6PD, 1.3  mM reduced nico-
tinamide adenine dinucleotide phosphate and 3.3  mM 
each of glucose-6-phosphate and magnesium chloride. 
Stock solutions of CQ/QN was prepared in water and 
added to the wells to a final concentration of 5 µM; an 
equivalent volume of buffer was included in control 
wells. Metabolic activity of the enzymes was halted at 
pre-determined times by the addition of one-part ice-
cold methanol containing 0.5  µg/mL D3-primaquine as 
internal standard. The samples were kept on ice for an 
hour and then centrifuged (14,000  rpm; 4  °C; 10  min). 
Clear supernatants were collected for ultra-performance 
liquid chromatography-mass spectrometry (UHPLC-
MS) analysis. All assays were performed in duplicate to 
observe intra-assay variations and repeated at separate 
days for inter-day comparisons. Controls included sub-
strate incubation without enzyme or start solutions and 
incubations without the substrate.
Hepatocyte incubations
Suspensions of pooled human hepatocytes were thawed 
from cryopreserved vials and recovered with the sup-
plier-provided recovery media (containing buffered 
saline with 2 % fetal bovine serum and 300 mM glucose). 
This was followed by centrifugation (300g, 5 min) to pel-
let the cells, which were then re-suspended in the plating 
media provided by the suppliers. Cell viability was deter-
mined based on cell counts using a Bio-Rad automated 
cell counter (Hercules, CA, USA). The cell density was 
adjusted to approximately 1 million viable cells/mL in 
the plating media and incubated with 20 µM PQ at 37 °C 
in a humidified atmosphere of 95 % air and 5 % CO2 in 
an Eppendorf incubator (Hauppauge, NY, USA) with 
an attached shaker set at 100  rpm. In addition, incuba-
tion plates contained 5 µM CQ/QN or equal volume of 
the plating media. In parallel, substrate-free and cell-free 
incubations were performed as controls. At each time 
point, aliquots were taken for cell viability measurement. 
Reactions were quenched using two volumes of ice-
cold methanol containing 0.5  µg/mL 6-D3-primaquine 
as internal standard at pre-determined time points 
(between 0 and 120 min).
Once metabolic reactions were quenched, the incuba-
tion mixtures were vortexed and kept at −20  °C for at 
least 4  h before further analysis. Clear supernatants of 
centrifuged samples (10,000g, 4 °C, 10 min) were dried in 
a Speedvac® and reconstituted in methanol for UHPLC-
MS analysis.
Page 4 of 12Fasinu et al. Malar J  (2016) 15:466 
Detection, identification and quantification of metabolites
Methods for simultaneous analysis of PQ and its metab-
olites using the UHPLC-MS were reported earlier [25]. 
This involved the use of a BEH Shield RP18 column 
(100 mm × 2.1 mm ID, 1.7 mm) equipped with an LC-18 
guard column (Vanguard 2.1  ×  5  mm, Waters Corp, 
Milford, MA, USA) on an ACQUITY UHPLC™ system 
(Waters) to which a conditioned auto-sampler (at 20  °C) 
was attached. Metabolites earlier identified, based on 
retention time, high resolution mass and MS–MS frag-
mentation pattern, were individually searched for and pro-
filed against time in the presence and absence of CQ/QN.
Results
PQ is metabolized rapidly by both CYP2D6 and MAO. 
CYP2D6 is known to mediate ring oxidation and demeth-
ylation steps, while MAO catalyzes oxidative deamination 
of the side chain. The effect of 5 µM each of CQ and QN 
on the generation of known CYP2D6- and MAO-depend-
ent metabolites of 20 µM PQ or its individual enantiomers 
was assessed using recombinant human enzymes. The 
influence of the two anti-malarial drugs on the genera-
tion of secondary metabolites in human hepatocytes was 
also investigated. In general, the oxidation of the quino-
line ring proved very sensitive to the presence of CQ/QN, 
whereas the formation of the deaminated products was 
generally not markedly inhibited. The structures of the 
major metabolites are presented in Fig. 1.
Influence of CQ and QN on CYP2D6‑dependent PQ 
metabolites
PQ was steadily depleted to varying degrees in the incu-
bation mixtures with recombinant CYP2D6 such that 
by 2 h, 65, 50 and 72 % of the racemic, (+)- and (−)-PQ 
remained, respectively. Both CQ and QN suppressed this 
depletion with all three substrates such that more than 
90 % of the substrates remained after 2 h (Fig. 2a–c).
The major metabolites from CYP-2D6-mediated 
pathway were 2-, 3-, and 4-hydroxyprimaquine, 
5,6-orthoquinone product from 5-hydroxyprimaquine 
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Fig. 1 A putative pathway of PQ metabolism in human hepatocytes. Uridine‑diphosphate‑glucuronic acid which is co‑factor necessary for 
glucuronidation catalyzed by UDPGT (Uridine‑diphosphate glucuronosyltransferase); CYP cytochrome P450; ALDH aldehyde dehydrogenase) (First 
published by Fasinu et al. [21])
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and PQ alcohol (as earlier reported) [9]. The for-
mation of 2-hydroxyprimaquine and the 5,6-ortho-
quinone predominated with (+)-PQ, while the 
3-hydroxy- and 4-hydroxyprimaquine were formed more 
from the (−)-PQ. Quantitatively, 2-hydroxyprimaquine 
was four times more abundant from (+)-PQ than from 
(−)-PQ. Although the concentration of 2-hydroxypri-
maquine peaked at 20  min with all substrates, 50  % of 
the peak concentration was already achieved by 5  min. 
CQ and QN completely suppressed the initial metabolite 
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Fig. 2 The influence of chloroquine and quinine on the CYP2D6‑mediated depletion of racemic PQ (a) and its enantiomers (b, c); and formation of 
2‑hydroxyprimaquine from racemic PQ (d) and e, f over 2 h of incubation. Each point represents values: mean ± S.D. (n = 4)
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surge, with some metabolite appearing after an initial lag 
time (Fig. 2).
Unlike 2-hydroxyprimaquine, 3- and 4-hydroxypri-
maquine were formed more readily from (−)-PQ than 
in (+)-PQ (2:1 and 5:1, respectively) (Fig.  3). Both 
3-hydroxy- and 4-hydroxyprimaquine have sharp early 
rises, which were again completely suppressed by CQ and 
QN at the early stages, then appearing in limited amounts 
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Fig. 3 The influence of chloroquine and quinine on the CYP2D6‑mediated formation and kinetics of 3‑hydroxyprimaquine from racemic PQ (a) and 
its individual enantiomers (b, c); and on the formation of 4‑hydroxyprimaquine from racemic PQ (d) and its enantiomers (e, f). Each point represents 
values mean ± S.D. (n = 4)
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after 5 min. The inhibitory effect of QN on the formation 
of the monohydroxyprimaquines appeared to be slightly 
more than the equimolar CQ, but the two were generally 
comparable. Both CQ and QN completely suppressed the 
formation of the 5,6-orthoquinone (Fig. 4), presumptively 
derived from 5-hydroxyprimaquine. Both CQ and QN 
show only moderate inhibition on CYP2D6-catalyzed 
formation of the PQ terminal alcohol. Interestingly, in 
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Fig. 4 The inhibitory effect of chloroquine and quinine on the formation and time‑course of the PQ 5,6‑orthoquinone generated from racemic PQ 
(a) and its individual enantiomers (b, c) by CYP2D6; and on the formation of primaquine alcohol from CYP2D6‑catalyzed metabolism of racemic PQ 
(d) and its enantiomers (e, f). Each point represents values mean ± S.D. (n = 4)
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contrast to the effect on ring-hydroxylated metabolites, 
CQ caused greater inhibition (about 70  %) of CYP2D6-
mediated formation of PQ alcohol from (+)-PQ while 
QN caused only about 45  % inhibition, respectively 
(Fig. 5).
Other minor metabolites generated by CYP2D6-medi-
ated metabolism of PQ include dihydroxyprimaquine (m/z 
292) and two that appear to be quinone-imine derivatives 
of dihydroxyprimaquine (m/z 290). All of these minor 
metabolites were completely suppressed by CQ and QN.
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Influence of CQ and QN on MAO‑dependent PQ 
metabolites
The metabolism of PQ by MAO-A showed a marked 
enantioselectivity, with (−)-PQ being depleted four times 
faster than (+)-PQ (Fig. 2b). This depletion was not sig-
nificantly affected by CQ or QN with any of the sub-
strates until 1 h, after which a very modest inhibition was 
observed (Fig.  5a–c). The only major metabolite from 
MAO-dependent metabolism was the alcohol formed by 
oxidative deamination of the terminal amine. It is formed 
twice as much from (−)-PQ compared to (+)-PQ. By 2 h, 
CQ and QN caused about 60 % inhibition of the forma-
tion of PQ alcohol with both PQ enantiomers (Fig. 5d–f).
Influence of CQ and QN on PQ metabolites generated 
from human hepatocytes
PQ depletion and metabolite production from hepato-
cyte incubation monitored via UHPLC-MS/MS demon-
strated a faster metabolic rate for (−)-PQ as compared 
to (+)-PQ. The rate of metabolism was profiled against 
time, yielding an initial half-life of 3.65 and 1.08  h for 
(+)- and (−)-PQ, and elimination rate constants (ʎ) of 
0.19 and 0.64  h−1, respectively. The calculated in  vitro 
intrinsic clearance (Clint) was 2.55 and 8.49 (µL/min)/
million cells for (+) and (−)-PQ, respectively. Metabo-
lism was observed via oxidative deamination of the ter-
minal amine, hydroxylation of the quinoline ring, and 
what appears to be a third path, carbamoylation and 
glucuronidation of the terminal amine (m/z 480). The 
major deaminated metabolites were CPQ, PQ terminal 
alcohol, a cyclized side chain derivative from the alde-
hyde (m/z 241), cyclized carboxylic acid derivative (m/z 
257), a quinone-imine product of hydroxylated CPQ (m/z 
289), CPQ glucuronide (m/z 451), and the glucuronide of 
PQ alcohol (m/z 437). All were preferentially generated 
from the (-)-PQ. The major quinoline oxidation product 
(m/z 274) and 4-hydroxyprimaquine were preferentially 
formed from (+)-PQ. A prominent conjugate (m/z 422) 
(seemingly a glycosylated PQ, (but perhaps reflecting a 
fragment or degradation product of another metabolite) 
was also preferentially (+)-PQ-derived. The PQ carba-
moyl glucuronide metabolite (m/z 480) accumulated 
linearly over the incubation period, and was exclusively 
generated from (+)-PQ.
CQ and QN had no effect on the primary amine oxi-
dation products (CPQ or PQ alcohol or the cyclized 
aldehyde) (Fig. 6). However, surprisingly they did inhibit 
substantially the appearance of the glucuronides of CPQ 
and PQ alcohol. They also inhibited the appearance of 
the m/z 257 metabolite with a similar pattern, suggest-
ing that it may be derived from the CPQ conjugate. The 
formation of 4-OH-PQ and the quinone-imine (m/z 274) 
were essentially completely suppressed, and the m/z 422 
metabolite was very strongly suppressed (90–95  %) by 
both CQ and QN. The apparent quinone-imine of CPQ 
(m/z 289) was partially suppressed, but more promi-
nently by CQ than QN. The carbamoyl glucuronide of 
PQ (m/z 480) was not affected.
Discussion
The unique therapeutic indications for PQ and the 
absence of alternatives have made it indispensable in the 
treatment of P. vivax malaria, despite its known haemo-
toxicity in individuals with genetic deficiency in G6PD. 
The efficacy and the haemotoxicity of PQ, as well as 
other 8-AQs, appears to be related to active metabolites, 
although the specific pathways and metabolites responsi-
ble, as well as their sites of formation and mechanisms of 
action, remain unclear.
Following earlier substantive clinical reports [13, 15, 
16] that CQ and QN are capable of altering the thera-
peutic and toxicological responses to 8-AQs, including 
PQ, and from recent findings of new human metabo-
lites of PQ [9, 21], it is important to understand how CQ 
and QN might alter human PQ metabolism. The present 
study aimed to address these issues.
In an overview, PQ is metabolized via two pri-
mary phase I pathways, namely: hydroxylation prod-
ucts derived from CYP-mediated oxidation, especially 
CYP2D6; and oxidative deamination of the side chain 
affording the terminal alcohol or carboxylic acid, pri-
marily mediated by MAO-A (though CYP2D6 can also 
produce the PQ alcohol). In addition, a number of glu-
curonide conjugates of these phase I metabolites are 
formed, and an unusual (but not unknown, [26, 27]) car-
bamoylation/glucuronidation of the parent is observed 
[21]. CYP2D6-mediated metabolism of PQ is known to 
produce mono- and dihydroxylated primaquines and 
their quinone-imine products [9]. In human hepatocytes, 
a more limited suite of metabolites was observed, with 
the ring oxidation products quinone-imine m/z 274 and 
the 4-OH-PQ predominant from (+)-PQ, while the oxi-
dation of the terminal amine was the major metabolic 
route with (−)-PQ [21]. In addition, the PQ-carbamoyl-
glucuronide was exclusively formed from (+)-PQ.
Another metabolite (m/z 422, apparent PQ-glucoside) 
seems to be predominantly derived from (+)-PQ, per-
haps indirectly. It is of interest in that although it can 
be formed non-enzymatically, it also appears to arise in 
hepatocytes by an apparent enzymatic mechanism. Fur-
ther studies are underway on this metabolite to deter-
mine its origin.
The effects of CQ and QN observed in the present 
studies were most striking for CYP2D6 inhibition, with 
very modest effects on the oxidative deamination prod-
ucts of MAO. In hepatocytes, the inhibitory effects were 
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most striking on the CYP2D6 related products. The 
presence of CQ and QN did not appear to significantly 
inhibit the MAO-dependent pathway in hepatocytes. 
The inhibitory effects on CYP2D6 appeared to enhance 
the MAO-mediated metabolism as demonstrated in a 
mild increase in formation of CPQ, and the metabolites 
corresponding to m/z 241. A surprising inhibition was 
observed, however, on the formation of the glucuronides 
of CPQ and PQ alcohol in the human hepatocytes. This 
would be expected to facilitate the accumulation of the 
primary oxidative deamination metabolites. This finding 
is consistent with the report that CQ increased circulat-
ing CPQ concentrations when co-administered with PQ 
in humans [16]. The implications of this are not known, 
but such metabolites could theoretically exert more pro-
nounced pharmacodynamic effects and may contribute 
to the observed alteration in PQ response in the presence 
of CQ and QN.
The profound effects of CQ and QN on the CYP2D6-
generated metabolites was not particularly surpris-
ing result, since both of these drugs have demonstrated 
potential for inhibition of CYP2D6 in human studies 
[18, 28]. The metabolism results from the incubation 
with human hepatocytes might be presumed to provide 
a closer picture to in  vivo realities. Although CQ/QN 
suppressed the extent of the formation of a number of 
metabolites in the human hepatocytes, their inability to 
alter the clearance and other pharmacokinetic param-
eters of PQ suggests that the facilitation of one metabolic 
pathway counters the inhibitory effect on the other. Any 
observed pharmacodynamic changes therefore could 
result from the changes in the metabolite profiles.
For moderate CYP2D6 inhibitors like CQ and QN, sub-
strate-specific or orientation/conformation-specific inhi-
bition may be expected. This may explain varying degrees 
of inhibition on the individual CYP2D6 metabolites of PQ 
or the individual enantiomer substrates. However, such 
dramatic inhibition of the formation of the mono-hydrox-
ylated primaquines as was observed at the early time 
points may have significant pharmacodynamic implica-
tions. This might favour alternative metabolic pathways 
leading to significant changes in therapeutic response, 
and may play major roles in the earlier observation of mit-
igated toxicity when PQ was combined with CQ and QN.
However, it seems difficult to harmonize these find-
ings with the well-demonstrated enhancement of PQ 
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anti-malarial efficacy by QN and CQ and the recent obser-
vations suggesting that CYP2D6 activity is essential to the 
anti-malarial efficacy of PQ [17, 29]. Overall, it raises the 
question of other mechanisms of action for these drugs, 
and perhaps important roles of other PQ metabolites that 
are not CYP2D6-dependent. For example, CQ and QN may 
affect transport processes for cellular uptake or extrusion of 
PQ or metabolites in a manner that could affect the overall 
efficacy or toxicity of PQ. Or the pathway to hydroxylated 
PQ products from other CYPs could be favoured, yielding 
active metabolites not seen in the absence of CQ or QN. 
In addition, the abundance of deaminated products in the 
presence of CQ/QN might be shunted into pathways that 
yield active metabolites with reduced toxicity. All of these 
possibilities must await further study, and especially the 
study in the clinic, where the interaction of PQ with QN 
and CQ can be assessed in terms of new knowledge of PQ 
metabolites and new methods for quantitating these.
Conclusions
This study has been able to assess the influence of CQ/
QN on the multiple pathways of PQ metabolism. The 
identified PQ metabolites showed products of CYP-
dependent ring oxidation, MAO-catalyzed oxidation of 
the terminal amine and phase II conjugation products. 
Both CQ and QN strongly inhibited the ring oxidation 
pathway. The suppression of CYP-generated metabolites 
in favor of the oxidative deamination of the side chain 
and the abundance of the resultant deaminated metabo-
lites may raise the question of the roles of these metab-
olites in PQ activity and toxicity. The phase II reactions 
were also moderately inhibited by CQ/QN. The oxidation 
of the terminal amines and associated metabolites were 
generally not influenced by the presence of CQ and QN.
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